US$ 28.01
fda compounding glp 1 is short-sighted on GLP-1s FDA and Novo Nordisk Warned
Description
The study used electronic health records (EHRs) from the TriNetX US Collaborative Network, covering over 100 million patients

GLP-1 also signals the brain to induce satiety (the feeling of being full) and slows down the rate at which the stomach empties, thus reducing hunger and controlling food intake
Unrealistic expectations are common
Diabetes Care (2015) 38(12):22419
Physiological reviews, 87(4), 14091439